|
JP2020094042A
|
|
Solid preparation containing rivaroxaban and flavoring agent
|
|
JP2020083887A
|
|
Tablet containing azilsartan
|
|
JP2020083886A
|
|
Tablet containing azilsartan
|
|
JP2020066634A
|
|
Granules containing enteric polymer and disintegrator
|
|
JP2020029455A
|
|
Solid preparation containing finely crushed rivaroxaban
|
|
JP2020002129A
|
|
Duloxetine hydrochloride-containing granules with improved photochromic properties
|
|
JP2019218339A
|
|
Intraoral disintegrable tablet that contains flavoring agent-containing granules and is easier to take
|
|
JP2020176090A
|
|
Method for Producing Solid Formulation Containing Dasatinib Anhydride
|
|
JP2019172672A
|
|
Solid preparation containing sitagliptin or salt thereof
|
|
JP2019085425A
|
|
Calcium folinate-containing tablet
|
|
JP2019147798A
|
|
Method for producing solid preparation with crystalline form of dasatinib anhydride stably maintained
|
|
JP2019070045A
|
|
Silodosin-containing tablet in which stability is improved
|
|
JP2020121776A
|
|
Desiccant package of esomeprazole preparation
|
|
JP2020121950A
|
|
Solid preparation
|
|
JP2019137669A
|
|
Industrial manufacturing method for compression-molded tablets containing relatively high density granules
|
|
JP2019089758A
|
|
Method for improving dissolution in celecoxib-containing tablets
|
|
JP2020023466A
|
|
Orally disintegrating tablets with reduced bitterness of fast-dissolving drugs
|
|
JP2019081753A
|
|
Enteric-coated preparation having improved leachability of duloxetine hydrochloride
|
|
JP2020029447A
|
|
Granule containing enteric polymer and anti-attachment agent
|
|
JP2019135226A
|
|
Method for producing compression molded preparation having improved acid resistance of enteric coated granule
|
